CLUSTER filed Aug 20, 2026 at 16:10 ET
Keros Therapeutics insiders executed a mixed cluster: one director bought $10K worth of shares, while three C-suite officers and one director sold a combined $101K on the same day. The selling is concentrated among senior executives (CSO, CLO, VP Finance) at identical prices, suggesting coordinated liquidity or tax-related selling rather than a bearish signal, but the asymmetry between a small director buy and larger officer sells warrants attention. At $220M market cap, the $111K total is ~0.05% of market cap, trivial in magnitude, but the C-suite cluster sell pattern is notable given the company's pre-revenue biotech status and upcoming pipeline catalysts.